http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CH-710991-A2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_79fc4564f7a195585b077bcf74fd7e1e |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-216 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-451 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2031 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-215 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06 |
| filingDate | 2015-04-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_899bd84226af706fd0b7a56c94fdb602 |
| publicationDate | 2016-10-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CH-710991-A2 |
| titleOfInvention | Compositions comprising combinations of 4,5-diacetylrhein analogues and mammalian carboxylesterase inhibitors. |
| abstract | This disclosure provides compositions and methods for protecting a compound comprising a rhein ester moiety from the metaholic transformation with hydrolases. In one aspect, the invention is directed to increasing the bioavailability and tissue distribution of the diacetylrhein anti-osteoarthritis compound by means of protecting the human intestinal carboxylesterase inactivation compound with an inhibitor. specific for this carboxylesterase such as loperamide. Specific approaches to limiting metabolic transformation include the use of inhibitors and carboxylesterase substrates to inhibit the metabolism of compounds. In addition, methods of treating or preventing diseases, including osteoarthritis, in mammals and in particular in humans are also described. |
| priorityDate | 2015-04-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 1387.